Anticancer efficacy and toxicity of oral GMO-paclitaxel in a hormone refractory prostate cancer model
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, D.B. | - |
dc.contributor.author | Jang, J. | - |
dc.contributor.author | Cho, Y.-H. | - |
dc.contributor.author | Yoon, M.S. | - |
dc.contributor.author | Chung, H.-S. | - |
dc.contributor.author | Park, Y.T. | - |
dc.contributor.author | Choi, Y.W. | - |
dc.contributor.author | Kim, S.W. | - |
dc.date.available | 2019-06-10T06:33:06Z | - |
dc.date.issued | 2006-02 | - |
dc.identifier.issn | 0494-4747 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/25532 | - |
dc.description.abstract | Purpose: We wanted to evaluate the efficacy and toxicity of the newly developed oral glyceryl monooleate (GMO)-paclitaxel in a hormone refractory prostate cancer model. Materials and methods: A paclitaxel formulation was prepared from GMO, tricaprylin, Tween®80 and paclitaxel. The tumor cells of prostate cancer (DU-145 cells) were incubated and then put into different paclitaxel concentrations. The tumoricidal activity was measured by using an indirect methylthiazol-2-yl-2,5-diphenyl tetrazolium bromide (MTT) assay. Cells of the DU-145 cell line were subcutaneously heterotransplanted into 18 nude mice, and they developed prostate cancer. The 18 mice were divided into 3 groups; the control group was injected with the DU-145 cell line (n=6), the GMO group was injected with GMO after the DU-145 cells were injected (n=6), and the oral GMO-paclitaxel group was injected with oral GMO-paclitaxel after the DU-145 cells were injected (n=6). The tumor volume was measured every week and the main organs were evaluated pathologically to determine the toxicity. Results: On the MTT assay, the control group and the GMO group did not display cytotoxicity. However, treatment with the various GMO-paclitaxel formulations (0.1 μg/ml, 1 μg/ml, 10 μg/ml) for treating the DU-145 cell line cancer induced cytotoxicity in a dose dependent fashion. The tumor volumes were not significantly changed in the group that was administered oral GMO-paclitaxel. However, there were significantly increased tumor volumes in the control group and the GMO group (p< 0.05). Toxic changes were not detected in liver and kidney, and there was normal cellularity with a normal myeloid:erythroid ratio in the mice after the administration of oral GMO-paclitaxel. Conclusions: The newly developed oral GMO-paclitaxel has a remarkable cytotoxic effect against DU-145 cells without systemic toxicity. Therefore, oral GMO-paclitaxel therapy promises to be a safe and effective modality for treating hormone refractory prostate cancer, and it can possibly replace IV paclitaxel. | - |
dc.format.extent | 7 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.publisher | Korean Urological Association | - |
dc.title | Anticancer efficacy and toxicity of oral GMO-paclitaxel in a hormone refractory prostate cancer model | - |
dc.type | Article | - |
dc.identifier.doi | 10.4111/kju.2006.47.2.143 | - |
dc.identifier.bibliographicCitation | Korean Journal of Urology, v.47, no.2, pp 143 - 149 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-33646563437 | - |
dc.citation.endPage | 149 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 143 | - |
dc.citation.title | Korean Journal of Urology | - |
dc.citation.volume | 47 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Hormone refractory prostate cancer | - |
dc.subject.keywordAuthor | Paclitaxel | - |
dc.subject.keywordPlus | bromine derivative | - |
dc.subject.keywordPlus | glycerol stearate | - |
dc.subject.keywordPlus | paclitaxel | - |
dc.subject.keywordPlus | polysorbate 80 | - |
dc.subject.keywordPlus | trioctanoin | - |
dc.subject.keywordPlus | animal cell | - |
dc.subject.keywordPlus | animal experiment | - |
dc.subject.keywordPlus | animal model | - |
dc.subject.keywordPlus | animal tissue | - |
dc.subject.keywordPlus | antineoplastic activity | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | bioassay | - |
dc.subject.keywordPlus | bone marrow | - |
dc.subject.keywordPlus | cancer chemotherapy | - |
dc.subject.keywordPlus | cancer size | - |
dc.subject.keywordPlus | concentration response | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | cytotoxicity | - |
dc.subject.keywordPlus | disease model | - |
dc.subject.keywordPlus | dose response | - |
dc.subject.keywordPlus | drug blood level | - |
dc.subject.keywordPlus | drug dose regimen | - |
dc.subject.keywordPlus | drug efficacy | - |
dc.subject.keywordPlus | drug formulation | - |
dc.subject.keywordPlus | drug mechanism | - |
dc.subject.keywordPlus | drug safety | - |
dc.subject.keywordPlus | erythroid cell | - |
dc.subject.keywordPlus | histopathology | - |
dc.subject.keywordPlus | incubation time | - |
dc.subject.keywordPlus | liver toxicity | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | mouse | - |
dc.subject.keywordPlus | nephrotoxicity | - |
dc.subject.keywordPlus | nonhuman | - |
dc.subject.keywordPlus | prostate cancer | - |
dc.subject.keywordPlus | tumor cell | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.